Depiction of 2 different mouse xenograft models of myeloid diseases treated with miR-146a conjugate therapy that enters myeloid cells through surface receptors. (Left) Mouse with human del(5q) AML. (Right) Mouse with human lymphoma that developed myeloid-derived CRS upon treatment with CD19 CAR-T cell therapy. Inside the myeloid cell, the delivered miR-146a targets TRAF6 and IRAK1, that block NF-κB–mediated production of inflammatory cytokines IL1 and IL6. del(5q), deletion of chromosome 5q.